Principal Investigator:
Madeline Rice, Ph.D.
Co-Investigator:
Sarah Fowler, Ph.D.
Co-Investigator: Judith Hsia, M.D
PEACE Home Page
he Prevention of Events with Angiotensin Converting Enzyme
Inhibition (PEACE) trial is a randomized placebo controlled,
multi-center multi-national trial initiated in November 1995 by
the National Heart, Lung and Blood Institute (NHLBI). The
primary objective of the trial is to test whether the addition of
the angiotensin converting enzyme (ACE) inhibitor, trandolapril,
to standard therapy will reduce the incidence of cardiovascular
mortality, non-fatal myocardial infarction, or the occurrence of
a coronary artery bypass graft surgery (CABG) or percutaneous
transluminal coronary angiography (PTCA) in patients with
documented coronary artery disease and preserved left ventricular
function. Over one hundred and eighty-five clinical centers in
the United States, Puerto Rico, Canada, and Italy completed
recruiting 8,290 patients for the study in June 2000. Follow-up
ended on December 31, 2003 with an average follow-up of over 4
years. Results will be reported in November 2004. The George
Washington University Biostatistics Center is serving as the
Clinical and Statistical Coordinating Center for this trial.
|
